Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031

Rivaroxaban

Ifeanyichukwu Ifechidere: DOAC Interference in Coagulation Tests - Are You Spotting It?
May 12, 2026, 14:46 | Voices
Ifeanyichukwu Ifechidere: DOAC Interference in Coagulation Tests - Are You Spotting It?
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post…
Paul Logan: Decoding the Words 'He's on blood thinners'
Apr 30, 2026, 17:13 | Voices
Paul Logan: Decoding the Words 'He's on blood thinners'
Paul Logan, Founder of Advanced Practice Ready, shared a post on LinkedIn: "'He's on blood…
Shalini R: Not All Blood Thinners Are the Same
Apr 23, 2026, 17:57 | Voices
Shalini R: Not All Blood Thinners Are the Same
Shalini R, Registered Nurse at Saudi German Health, shared a post on LinkedIn: ''Notes:10 Not…
Ifeanyichukwu Ifechidere: The Critical Role of Calibrator Specificity in Anticoagulation Monitoring
Apr 22, 2026, 04:43 | Voices
Ifeanyichukwu Ifechidere: The Critical Role of Calibrator Specificity in Anticoagulation Monitoring
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post…
Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation - Cardiology Insights and Heart Health
Apr 15, 2026, 17:30 | Science
Rivaroxaban versus Aspirin after Atrial Fibrillation Ablation - Cardiology Insights and Heart Health
Cardiology Insights and Heart Health shared a post on LinkedIn about a recent article by…
Sara Altayeb: ESC 2026 Clinical Pearls for Bleeding on Anticoagulation
Apr 13, 2026, 08:35 | Insight
Sara Altayeb: ESC 2026 Clinical Pearls for Bleeding on Anticoagulation
Sara Altayeb, Internal Medicine Specialist at Virtual Sudan Clinic, shared on LinkedIn: ''Bleeding on Anticoagulation…
Najmul Hasan Forhad: A Simple Framework for Mastering Anticoagulant Therapy
Apr 12, 2026, 16:53 | Insight
Najmul Hasan Forhad: A Simple Framework for Mastering Anticoagulant Therapy
Najmul Hasan Forhad, Medical Laboratory Technician at Doctors Without Borders, shared on LinkedIn: ''Hello ASCP…
Chokri Ben Lamine: Anticoagulation Switching Pearls
Apr 8, 2026, 14:17 | Voices
Chokri Ben Lamine: Anticoagulation Switching Pearls
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at…
Abdul Mannan: A Clinical Framework for Direct Oral Anticoagulant Reversal in Acute Bleeding
Apr 4, 2026, 14:40 | Voices
Abdul Mannan: A Clinical Framework for Direct Oral Anticoagulant Reversal in Acute Bleeding
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn: "Four…
Anas Ibraheem: Clearing the Long-Standing Debate on Bleeding Risk in VTE Anticoagulation
Apr 1, 2026, 13:48 | Voices
Anas Ibraheem: Clearing the Long-Standing Debate on Bleeding Risk in VTE Anticoagulation
Anas Ibraheem, Medical Oncology Fellow at The London Clinic, shared  Abdulrahman Nasiri's post on LinkedIn:…
Emmanuele Kouvousis: DOAC Dose Adjustments for Older Patients
Mar 31, 2026, 12:50 | Voices
Emmanuele Kouvousis: DOAC Dose Adjustments for Older Patients
Emmanuele Kouvousis, Non-Invasive Cardiologist, Scientific Director at Affidea, shared a post on LinkedIn: "DOAC dose…
Karim Ahmed: Why The Right DOAC Choice Still Depends on The Patient
Mar 29, 2026, 11:40 | Voices
Karim Ahmed: Why The Right DOAC Choice Still Depends on The Patient
Karim Ahmed, Clinical Pharmacist at Palm Beach Accountable Care Organization, shared a post on LinkedIn:…
Amy Delderfield: One Trial, Big Implications for Anticoagulant Choice
Mar 28, 2026, 18:41 | Voices
Amy Delderfield: One Trial, Big Implications for Anticoagulant Choice
Amy Delderfield, Founder of Medicine Central, STEM Advisor to the UN, shared a post on…
Yonah S. Tehrani: Providing Clarity for Anticoagulant Selection in Acute Venous Thromboembolism
Mar 26, 2026, 17:25 | Science
Yonah S. Tehrani: Providing Clarity for Anticoagulant Selection in Acute Venous Thromboembolism
Yonah S. Tehrani, Physician at Shaare Zedek Medical Center, Jerusalem, shared a post on LinkedIn about…
Edward Lee Carter: Are All DOACs Truly Interchangeable in Real-World Practice?
Mar 26, 2026, 15:47 | Voices
Edward Lee Carter: Are All DOACs Truly Interchangeable in Real-World Practice?
Edward Lee Carter, Clinical Pharmacist Practitioner at U.S. Department of Veterans Affairs, shared a post…
Mazou Ngou Temgoua: Why Does Apixaban Cause Less Bleeding than Rivaroxaban?
Mar 23, 2026, 15:46 | Science
Mazou Ngou Temgoua: Why Does Apixaban Cause Less Bleeding than Rivaroxaban?
Mazou Ngou Temgoua, Contract hospital practitioner at Châteauroux-Le Blanc Hospital Center, shared on LinkedIn about a…
Ala Eddin Sagar: Apixaban vs Rivaroxaban on This Week in Pulmonary and Critical Care Medicine
Mar 22, 2026, 16:21 | Insight
Ala Eddin Sagar: Apixaban vs Rivaroxaban on This Week in Pulmonary and Critical Care Medicine
Ala Eddin Sagar, Interventional Pulmonologist at King Faisal Specialist Hospital and Research Center - Madinah,…
Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
Mar 19, 2026, 17:14 | Science
Akinchan Bhardwaj: Differences in Bleeding Outcomes Among DOACs
Akinchan Bhardwaj, Consultant Interventional Cardiologist at Kauvery Hospital, shared a post on LinkedIn about a recent…
Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
Mar 18, 2026, 16:34 | Voices
Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
Richard Buka, Academic Clinical Lecturer at University of Birmingham, shared a post on LinkedIn about…
Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
Mar 16, 2026, 18:59 | Science
Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared a post on LinkedIn about…
Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
Mar 16, 2026, 16:14 | Voices
Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
Siobhan Calafiore, Senior Journalist at the limbic, shared a post on LinkedIn about a recent…
Abdul Mannan: Why Apixaban May Be the Safer Choice for Acute VTE
Mar 14, 2026, 15:11 | Voices
Abdul Mannan: Why Apixaban May Be the Safer Choice for Acute VTE
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn: "For…
Abdulrahman Nasiri: Most Important Concepts and the Clinical Shift the COBRRA Trial Brings to Practice
Mar 14, 2026, 14:45 | Voices
Abdulrahman Nasiri: Most Important Concepts and the Clinical Shift the COBRRA Trial Brings to Practice
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University,…
Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
Mar 13, 2026, 16:51 | Science
Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on…
Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
Mar 13, 2026, 16:44 | Voices
Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a…
Ney Carter Borges: A Safety Advantage of Apixaban over Rivaroxaban Without Clear Superiority
Mar 11, 2026, 23:05 | Science
Ney Carter Borges: A Safety Advantage of Apixaban over Rivaroxaban Without Clear Superiority
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a…
The Results of Landmark COBRRA Trial in Acute VTE Management - ISTH
Mar 11, 2026, 22:01 | Science
The Results of Landmark COBRRA Trial in Acute VTE Management - ISTH
International Society on Thrombosis and Haemostasis (ISTH) shared a post on LinkedIn about a recent article…
Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
Mar 11, 2026, 15:34 | Science
Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
Kymentie Ferdinande, PhD Researcher UNIPD at University of Padova, shared a post on LinkedIn about…
Gilles Soulat: Low-Dose Rivaroxaban Plus DAPT for LV Thrombus Prevention After Anterior STEMI
Mar 9, 2026, 15:30 | Voices
Gilles Soulat: Low-Dose Rivaroxaban Plus DAPT for LV Thrombus Prevention After Anterior STEMI
Gilles Soulat, Professor of Radiology at Paris Cité University, shared a post  on LinkedIn about a…
Jean Terrier: The Relationship Between DOAC Plasma Concentrations and Clinical Outcomes
Mar 4, 2026, 15:14 | Voices
Jean Terrier: The Relationship Between DOAC Plasma Concentrations and Clinical Outcomes
Jean Terrier, Clinical Pharmacologist and Toxicologist at University of Rhode Island, shared a post on LinkedIn about…
Ney Carter Borges: The APERITIF Trial Clarifies Rivaroxaban's Role in LVT
Feb 26, 2026, 14:48 | Science
Ney Carter Borges: The APERITIF Trial Clarifies Rivaroxaban's Role in LVT
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on…
GENB-OAC Study Insights from Gabrielle Sarlon and The Team
Feb 15, 2026, 06:04 | Science
GENB-OAC Study Insights from Gabrielle Sarlon and The Team
RPTH Journal shared on LinkedIn: ''New data about abnormal uterine bleeding under oral anticoagulants, Abnormal…
Shashank Joshi: Switching Among Oral Anticoagulants
Feb 2, 2026, 16:45 | Voices
Shashank Joshi: Switching Among Oral Anticoagulants
Shashank Joshi, Senior Consultant at Joshi Clinic and President of Indian Academy of Diabetes, shared…
Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
Jan 7, 2026, 13:21 | Science
Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
Bartosz Hudzik, Editorial Consultant at JACC Case Reports, shared on LinkedIn: ''New evidence on “aspirin…
Michael Makris Shares an Update on The Safety of Andexxa
Jan 1, 2026, 09:02 | Science
Michael Makris Shares an Update on The Safety of Andexxa
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on…
Samwel Mikaye: Anticoagulants vs Antiplatelets
Dec 28, 2025, 08:34 | Insight
Samwel Mikaye: Anticoagulants vs Antiplatelets
Samwel Mikaye, CEO of SaMik Medical Center, shared on LinkedIn: ''Anticoagulants vs Antiplatelets These are…
Shekher Bose on AstraZeneca's Voluntary Withdrawal of Andexxa
Dec 20, 2025, 18:15 | Insight
Shekher Bose on AstraZeneca's Voluntary Withdrawal of Andexxa
Shekher Bose, Client Partner at Beyondsight Intelligence, reposted Beyondsight Intelligence on LinkedIn: ''This marks the…
Nicolas Gendron on Sustainability in Anticoagulation and DOACs
Dec 16, 2025, 16:14 | Science
Nicolas Gendron on Sustainability in Anticoagulation and DOACs
Nicolas Gendron, Research Fellow, Hematologist at Boston Children’s Hospital, shared on LinkedIn: ''Anticoagulation and sustainability.…
Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
Dec 13, 2025, 16:09 | Science
Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
Brehanna Edwards, PGY-2 Health-System Pharmacy Administration and Leadership Resident at Ascension, shared on LinkedIn: ''Publication…
8 Posts Not to Miss From the ASH 2025 – Marc Carrier
Dec 12, 2025, 14:47 | Insight
8 Posts Not to Miss From the ASH 2025 – Marc Carrier
The American Society of Hematology Congress 2025 (ASH25) is officially underway in Orlando, Florida, from…
ASH25 Highlight - Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Dec 8, 2025, 08:27 | Science
ASH25 Highlight - Extended Anticoagulation in VTE: Apixaban vs Rivaroxaban
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on LinkedIn: ''ASH25 Highlight - Extended…
Dr. Rawnak Sharif: Managing Proximal Lower-Limb DVT or PE is No Longer Just About Choosing an Anticoagulant
Dec 5, 2025, 03:43 | Drugs
Dr. Rawnak Sharif: Managing Proximal Lower-Limb DVT or PE is No Longer Just About Choosing an Anticoagulant
Dr. Rawnak Sharif, Resident Medical Officer at Apollo Imperial Hospital, posted on LinkedIn: "Modern, Evidence-Based Management…
Ravi Kumar: Vitamin K Antagonists Remains the Gold Standard in APS
Nov 24, 2025, 14:16 | Insight
Ravi Kumar: Vitamin K Antagonists Remains the Gold Standard in APS
Ravi Kumar, Rheumatologist at Christian Medical College, shared on X: “Major Trials of DOACs in Antiphospholipid…
Claudio Laudani: DOACs Have Transformed the Landscape of Anticoagulation
Nov 18, 2025, 15:08 | Science
Claudio Laudani: DOACs Have Transformed the Landscape of Anticoagulation
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared on LinkedIn: ''Direct…
C. Michael Gibson and Atul Verma on OCEAN Trial: Rivaroxaban VS Aspirin in AF
Nov 8, 2025, 11:18 | Insight
C. Michael Gibson and Atul Verma on OCEAN Trial: Rivaroxaban VS Aspirin in AF
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:…
Alex McDonald: Much Needed Information on the Management of LVT
Nov 7, 2025, 02:33 | Science
Alex McDonald: Much Needed Information on the Management of LVT
Alex McDonald, Clinical Pharmacy Specialist at Spartanburg Regional Healthcare System, reposted from RPTH Journal on…
Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
Oct 29, 2025, 07:38 | Science
Thijs van Haaps and Team Show That Andexanet Alfa May Go Beyond Apixaban and Rivaroxaban
RPTH Journal shared a post on LinkedIn: "New in RPTH! Thijs van Haaps and team show…
Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
Sep 23, 2025, 06:40 | Innovation
Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
Richard Buka, Chair of HaemSTAR, shared on X: ”Bit of pharma news here. CSL Behring…
Rivaroxaban vs Apixaban in AFib and PAD - What the Data Say
Sep 11, 2025, 08:32 | Insight
Rivaroxaban vs Apixaban in AFib and PAD - What the Data Say
Mattia Galli, Assistant Professor at Sapienza Università di Roma, Associate Editor of European Heart Journal,…
Aymeric Couturier Shares Recent Studies on Anticoagulation and Atrial Fibrillation in Dialysis
Sep 3, 2025, 20:04 | Science
Aymeric Couturier Shares Recent Studies on Anticoagulation and Atrial Fibrillation in Dialysis
Aymeric Couturier, Nephrologist at American Hospital;Necker Hospital, shared on LinkedIn: ''Anticoagulation and atrial fibrillation in…
Anticoagulation Forum: Only 2 Weeks Left to Apply! Don’t Miss 2025 Virtual Boot Camp
Aug 14, 2025, 18:08 | Organizations
Anticoagulation Forum: Only 2 Weeks Left to Apply! Don’t Miss 2025 Virtual Boot Camp
Anticoagulation Forum shared an inviting post on LinkedIn: ''Only 2 weeks left to apply! Don’t…
Low-Intensity DOACs in VTE: Sapienza University Reports Long-Term Outcomes
Aug 12, 2025, 03:37 | Science
Low-Intensity DOACs in VTE: Sapienza University Reports Long-Term Outcomes
Friends of Mediterranean Journal of Hematology and Infectious Diseases Group shared a post by Giuseppe…
RPTH Journal: Rivaroxaban vs Warfarin in PE with RV Dysfunction
Aug 6, 2025, 12:52 | Insight
RPTH Journal: Rivaroxaban vs Warfarin in PE with RV Dysfunction
RPTH Journal shared a new study on LinkedIn: ''Do clinical outcomes differ between patients treated…
Oral Anticoagulation in VTE: Apixaban Safer and More Effective than Rivaroxaban or Warfarin
Aug 2, 2025, 17:34 | Insight
Oral Anticoagulation in VTE: Apixaban Safer and More Effective than Rivaroxaban or Warfarin
The Heart has published on X: “Oral Anticoagulation and Risk of Adverse Clinical Outcomes in…
Acute VTE in Women: Continue Contraception, Select the Right Anticoagulant
Aug 2, 2025, 04:31 | Science
Acute VTE in Women: Continue Contraception, Select the Right Anticoagulant
Richard Buka, Chair of HaemSTAR, shared a post on X: ”This deserves reposting Love the…
All: 55 Posts: 1 - 100
NewsFeed